A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Duvelisib (Primary) ; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Infinity Pharmaceuticals; Verastem Oncology
- 08 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Jul 2020.
- 08 Oct 2019 Planned primary completion date changed from 1 May 2019 to 1 Jul 2020.
- 07 Mar 2019 According to a Verastem Oncology Media Release, data from this study and NCT01882803, NCT02004522,,NCT01476657 was presented at the 23rd Annual International Congress on Hematologic Malignancies (ICHM), which took place February 28 to March 3, 2019, in Miami, Florida.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History